Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Kane Biotech Inc
KNBIF
Primary Symbol:
V.KNE
Healthcare
Biotechnology
Kane Biotech Inc. is a Canada-based biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (66 patents and patents pending, trade secrets and trademarks) and products developed by its own biofilm research expertise and acquired...
from research institutions. DispersinB, coactiv+, coactiv+, DermaKB, DermaKB Biofilm, and revive are trademarks of the Company. Its patented coactiv+ technology is specifically formulated to destabilize biofilm and create an environment for fast wound healing. In Wound Care & Surgical applications, in addition to revyve Antimicrobial Wound Gel, it is developing follow-on products with three applications: coactiv+ Antimicrobial Surgical Hydrogel, coactiv+ Antimicrobial Wound Gel Spray, and coactiv+ Antimicrobial Wound Rinse. The Company's other biofilm disruption technology is DispersinB.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSXV:KNE)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(75)
•••
francoisl13
X
View Profile
View Bullboard History
Comment by
francoisl13
on Nov 27, 2024 9:22am
RE:BioStem - Info on their distributor-partner...
Interesting point to note....Progenacare and Kane products are listed on the Venture Medical website...don't know if they were added after the Progenacare acquisition by BioStem or if Venture
...more
(75)
•••
francoisl13
X
View Profile
View Bullboard History
Post by
francoisl13
on Nov 27, 2024 9:19am
BioStem - Info on their distributor-partner...
BioStem increased sales by 116% in H1/2024 due to their partnership with Venture Medical signed late in 2023... Venture Medical - website GLTA!
Lahontan Gold Announces Filing of Santa Fe Technical Report
posted Nov 29, 2024 9:00am by
Lahontan Gold Corp.
-
|
Lahontan Gold is pleased to announce that the Company has filed on SEDAR+ an independent Technical Report and updated Mineral Resource Estimate ("MRE") titled "Santa Fe Project Technical Report," effective October 9, 2024, and dated November 27, 2024, for Lahontan's Santa Fe Mine gold and silver project, Santa Fe District, Mineral County, Nevada. ...read more
(75)
•••
francoisl13
X
View Profile
View Bullboard History
Post by
francoisl13
on Nov 27, 2024 9:12am
BioStem Technologies - Corporate Presentation
This looks like a very good news as it seems that BioStem distribution capabilities are better developed than the one of Progenacare...more to come... BioStem - Corporate Presentation GLTA!
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Nov 27, 2024 8:30am
New Press Release - Kane Biotech Announces Change in US Distribution Partner for revyve(TM) Antimicrobial Wound Gel
BioStem Technologies Signs Letter of Intent to Acquire Exclusive US Distribution Rights for revyve™ from ProgenaCare Global WINNIPEG, Manitoba, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company”, “Kane Biotech” or “Kane”) announces today that BioStem...
read article.
(75)
•••
francoisl13
X
View Profile
View Bullboard History
Post by
francoisl13
on Nov 22, 2024 3:07pm
New Scientific Article
Here's a link to the latest Kane scientific article dated November 19th, 2024; MDPI Article Nov.19,2024 GLTA!
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Nov 21, 2024 4:30pm
New Press Release - Kane Biotech to Release Third Quarter 2024 Financial Results on November 28, 2024
Conference Call to be held on December 3, 2024 WINNIPEG, Manitoba, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech”) will release its third quarter 2024 financial results after market close on Thursday, November 28, 2024.Kane Biotech management will...
read article.
(8)
•••
KevinOleary
X
View Profile
View Bullboard History
Comment by
KevinOleary
on Nov 19, 2024 8:36pm
RE:RE:RE:RE:RE:RE:RE:RE:New Press Release - Kane Biotech Announces Health Canada Approval of revyve(TM) Antimicrobial Wound Gel
You'll probably see the spray listed here before it gets delivered to Progena. https://www.progenacare.com/products/
(8)
•••
KevinOleary
X
View Profile
View Bullboard History
Comment by
KevinOleary
on Nov 15, 2024 2:30pm
RE:RE:RE:RE:RE:RE:RE:New Press Release - Kane Biotech Announces Health Canada Approval of revyve(TM) Antimicrobial Wound Gel
Yes francois, the holdup in getting to market after the FDA approved the dosage was scheduling with Halo, then shipping to Sweden for canning. Both of those factories have more customers than just KNE
...more
(72)
•••
MirrorWorldMan
X
View Profile
View Bullboard History
Comment by
MirrorWorldMan
on Nov 15, 2024 2:05pm
RE:New Press Release - Kane Biotech Announces Health Canada Approval of revyve(TM) Antimicrobial Wound Gel
This is an important milestone that allows a launch of a new product to Canadian consumers and a chance to demonstrate a working model for future commercializations. I have always been a firm
...more
(75)
•••
francoisl13
X
View Profile
View Bullboard History
Comment by
francoisl13
on Nov 15, 2024 12:42pm
RE:RE:RE:RE:RE:RE:New Press Release - Kane Biotech Announces Health Canada Approval of revyve(TM) Antimicrobial Wound Gel
Good piece of info KevinOleary...so, in short, the FDA released mention back in January was basically push aside when the higher dosage was approved. Good stuff...I didn't pick that one so, thanks
...more
(8)
•••
KevinOleary
X
View Profile
View Bullboard History
Comment by
KevinOleary
on Nov 15, 2024 11:57am
RE:RE:RE:RE:RE:New Press Release - Kane Biotech Announces Health Canada Approval of revyve(TM) Antimicrobial Wound Gel
2. The spray does not contact the propellant, so no new permission is needed for its use. They don't need any more FDA permission after the July 23, 2024 decision lets them use the higher
...more
(75)
•••
francoisl13
X
View Profile
View Bullboard History
Comment by
francoisl13
on Nov 15, 2024 9:28am
RE:RE:RE:RE:New Press Release - Kane Biotech Announces Health Canada Approval of revyve(TM) Antimicrobial Wound Gel
This is (2) excerpts from Kane's press release from last January regarding the 'wound gel spray' product; ''Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane
...more
(8)
•••
KevinOleary
X
View Profile
View Bullboard History
Comment by
KevinOleary
on Nov 14, 2024 6:19pm
RE:RE:RE:New Press Release - Kane Biotech Announces Health Canada Approval of revyve(TM) Antimicrobial Wound Gel
I meant they used FDA technical terms regarding the FDA decision.
(8)
•••
KevinOleary
X
View Profile
View Bullboard History
Comment by
KevinOleary
on Nov 14, 2024 5:25pm
RE:RE:New Press Release - Kane Biotech Announces Health Canada Approval of revyve(TM) Antimicrobial Wound Gel
They don't need approval for the spray. They got a decision that was NR on July 23 about it, but the NR was technical so most people didn't understand all the ramifications of it. They
...more
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >